Expression of atrial‑fetal light chains in cultured human cardiomyocytes after chemical ischemia‑reperfusion injury

Banaszkiewicz,Marta; Olejnik,Agnieszka; Krzywonos‑Zawadzka,Anna; Hałucha,Kornela; Bil‑Lula,Iwona

doi:10.3892/mmr.2021.12410

Expression of atrial‑fetal light chains in cultured human cardiomyocytes after chemical ischemia‑reperfusion injury

Authors:
- Marta Banaszkiewicz
- Agnieszka Olejnik
- Anna Krzywonos‑Zawadzka
- Kornela Hałucha
- Iwona Bil‑Lula
View Affiliations

Affiliations: Division of Clinical Chemistry and Laboratory Haematology, Department of Medical Laboratory Diagnostics, Faculty of Pharmacy, Wroclaw Medical University, 50‑556 Wroclaw, Poland
Published online on: September 3, 2021 https://doi.org/10.3892/mmr.2021.12410
Article Number: 770
Copyright: © Banaszkiewicz et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Atrial light chains (ALC1) are naturally present in adult heart atria, while ventricular light chains (VLC1) are predominant in ventricles. Degradation of VLC1 and re‑expression of ALC1 in heart ventricles are associated with heart disorders in response to pressure overload. The aim of the current study was to investigate changes in myosin light chain expression after simulated ischemia and simulated reperfusion (sI/sR). Human cardiomyocytes (HCM) isolated from adult heart ventricles were subjected to chemical ischemia. The control group was maintained under aerobic conditions. Myocyte injury was determined by testing lactate dehydrogenase (LDH) activity. The gene expression of ALC1, VLC1 and MMP‑2 were assessed by reverse transcription‑quatitive PCR. Additionally, protein synthesis was measured using ELISA kits and MMP‑2 activity was measured by zymography. The results revealed that LDH activity was increased in sI/sR cell‑conditioned medium (P=0.02), confirming the ischemic damage of HCM. ALC1 gene expression and content in HCM were also increased in the sI/sR group (P=0.03 and P<0.001, respectively), while VLC1 gene expression after sI/sR was decreased (P=0.008). Furthermore, MMP‑2 gene expression and synthesis were lower in the sI/sR group when compared with the aerobic control group (P<0.001 and P=0.03, respectively). MMP‑2 activity was also increased in sI/sR cell‑conditioned medium (P=0.006). In conclusion, sI/sR treatment led to increased ALC1 and decreased VLC1 expression in ventricular cardiomyocytes, which may constitute an adaptive mechanism to altered conditions and contribute to the improvement of heart function.

View Figures

View References

1	Abdelaziz AI, Segaric J, Bartsch H, Petzhold D, Schlegel WP, Kott M, Seefeldt I, Klose J, Bader M, Haase H and Morano I: Functional characterization of the human atrial essential myosin light chain (hALC-1) in a transgenic rat model. J Mol Med (Berl). 82:265–274. 2004. View Article : Google Scholar : PubMed/NCBI
2	Gudbjartsson DF, Holm H, Sulem P, Masson G, Oddsson A, Magnusson OT, Saemundsdottir J, Helgadottir HT, Helgason H, Johannsdottir H, et al: A frameshift deletion in the sarcomere gene MYL4 causes early-onset familial atrial fibrillation. Eur Heart J. 38:27–34. 2017. View Article : Google Scholar : PubMed/NCBI
3	Petzhold D, Lossie J, Keller S, Werner S, Haase H and Morano I: Human essential myosin light chain isoforms revealed distinct myosin binding, sarcomeric sorting, and inotropic activity. Cardiovasc Res. 90:513–520. 2011. View Article : Google Scholar : PubMed/NCBI
4	Cadete VJJ, Arcand SA, Lin HB and Sawicki G: Synergistic protection of MLC 1 against cardiac ischemia/reperfusion- induced degradation: A novel therapeutic concept for the future. Future Med Chem. 5:389–398. 2013. View Article : Google Scholar : PubMed/NCBI
5	Zhang C, Wang G, Ji Z, Liu Z, Hou L, Liu G and Wang J: Molecular cloning, characterisation and mRNA expression analysis of the sheep myosin light chain 1 gene. Gene. 569:51–59. 2015. View Article : Google Scholar : PubMed/NCBI
6	Reiser PJ: Current understanding of conventional and novel co-expression patterns of mammalian sarcomeric myosin heavy chains and light chains. Arch Biochem Biophys. 662:129–133. 2019. View Article : Google Scholar : PubMed/NCBI
7	Kurabayashi M, Komuro I, Tsuchimochi H, Takaku F and Yazaki Y: Molecular cloning and characterization of human atrial and ventricular myosin alkali light chain cDNA clones. J Biol Chem. 263:13930–13936. 1988. View Article : Google Scholar : PubMed/NCBI
8	Morano M, Zacharzowski U, Maier M, Lange PE, Alexi-Meskishvili V, Haase H and Morano I: Regulation of human heart contractility by essential myosin light chain isoforms. J Clin Invest. 98:467–473. 1996. View Article : Google Scholar : PubMed/NCBI
9	Schaub MC, Hefti MA, Zuellig RA and Morano I: Modulation of contractility in human cardiac hypertrophy by myosin essential light chain isoforms. Cardiovasc Res. 37:381–404. 1998. View Article : Google Scholar : PubMed/NCBI
10	Szczesna D: Regulatory light chains of striated muscle myosin. Structure, function and malfunction. Curr Drug Targets Cardiovasc Haematol Disord. 3:187–197. 2003. View Article : Google Scholar : PubMed/NCBI
11	Markandran K, Poh JW, Ferenczi MA and Cheung C: Regulatory light chains in cardiac development and disease. Int J Mol Sci. 22:43512021. View Article : Google Scholar : PubMed/NCBI
12	Khalina YN, Bartsch H, Petzhold D, Haase H, Podlubnaya ZA, Shpagina MD and Morano I: Reconstitution of ventricular myosin with atrial light chains 1 improves its functional properties. Acta Biochim Pol. 52:443–448. 2005.PubMed/NCBI
13	Zhong U, Tang K, Li H, Zhao D, Kou W, Xu S, Zhang J, Yang H, Li S, Guo R, et al: Rs4968309 in myosin light chain 4 (MYL4) associated with atrial fibrillation onset and predicts clinical outcomes after catheter ablation in atrial fibrillation patients without structural heart disease. Circ J. 83:1994–2001. 2019. View Article : Google Scholar : PubMed/NCBI
14	Arrell KK, Neverova I, Fraser H, Marbán E and Van Eyk JE: Proteomic analysis of pharmacologically preconditioned cardiomyocytes reveals novel phosphorylation of myosin light chain 1. Circ Res. 89:480–487. 2001. View Article : Google Scholar : PubMed/NCBI
15	Zhang C, Wang J, Wang G, Ji Z, Hou L, Liu Z and Chao T: Molecular cloning and mRNA expression analysis of sheep MYL3 and MYL4 genes. Gene. 577:209–214. 2016. View Article : Google Scholar : PubMed/NCBI
16	Machackova J, Barta J and Dhalla NS: Myofibrillar remodelling in cardiac hypertrophy, heart failure and cardiomyopathies. Can J Cardiol. 22:953–968. 2006. View Article : Google Scholar : PubMed/NCBI
17	Petzhold D, Simsek B, Meißner R, Mahmoodzadeh S and Morano I: Distinct interactions between actin and essential myosin light chain isoforms. Biochem Biophys Res Commun. 449:284–288. 2014. View Article : Google Scholar : PubMed/NCBI
18	Ritter O, Luther HP, Haase H, Baltas LG, Baumann G, Schulte HD and Morano I: Expression of atrial myosin light chains but not α-myosin heavy chains is correlated in vivo with increased ventricular function in patients with hypertrophic obstructive cardiomyopathy. J Mol Med (Berl). 77:677–685. 1999. View Article : Google Scholar : PubMed/NCBI
19	Nakao K, Yasue H, Fujimoto K, Jougasaki M, Yamamoto H, Hitoshi Y, Takatsu K and Miyamoto E: Increased expression and regional differences of atrial myosin light chain 1 in human ventricles with old myocardial infarction: Analyses using two monoclonal antibodies. Circulation. 86:1727–1737. 1992. View Article : Google Scholar : PubMed/NCBI
20	Cummins P, Price KM and Littler WA: Foetal myosin light chain in human ventricle. J Muscle Res Cell Motil. 1:357–366. 1980. View Article : Google Scholar : PubMed/NCBI
21	Sitbon YH, Yadav S, Kazmierczak K and Szczesna-Cordary D: Insights into myosin regulatory and essential light chains: A focus on their roles in cardiac and skeletal muscle function, development and disease. J Muscle Res Cell Motil. 41:313–327. 2020. View Article : Google Scholar : PubMed/NCBI
22	Gregorich ZR, Cai W, Lin Z, Chen AJ, Peng Y, Kohmoto T and Ge Y: Distinct sequences and post-translational modifications in cardiac atrial and ventricular myosin light chains revealed by top-down mass spectrometry. J Mol Cell Cardiol. 107:13–21. 2017. View Article : Google Scholar : PubMed/NCBI
23	Bil-Lula I, Lin HB, Bialy D, Wawrzyńska M, Diebel L, Sawicka J, Woźniak M and Sawicki G: Subthreshold nitric oxide synthase inhibition improves synergistic effects of subthreshold MMP-2/MLCK-mediated cardiomyocyte protection from hypoxic injury. J Cell Mol Med. 20:1086–1094. 2016. View Article : Google Scholar : PubMed/NCBI
24	Morano I: Tuning the human heart molecular motors by myosin light chairs. J Mol Med. 77:544–555. 1999. View Article : Google Scholar : PubMed/NCBI
25	Sawicki G, Leon H, Sawicka J, Sariahmetoglu M, Schulze CJ, Scott PG, Szczesna-Cordary D and Schulz R: Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: A new intracellular target for matrix metalloproteinase-2. Circulation. 112:544–552. 2005. View Article : Google Scholar : PubMed/NCBI
26	Kwan JA, Schulze CJ, Wang W, Leon H, Sariahmetoglu M, Sung M, Sawicka J, Sims DE, Sawicki G and Schulz R: Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro. FASEB J. 18:690–692. 2004. View Article : Google Scholar : PubMed/NCBI
27	Sariahmetoglu M, Skrzypiec-Spring M, Youssef N, Jacob-Ferreira AL, Sawicka J, Holmes C, Sawicki G and Schulz R: Phosphorylation status of matrix metalloproteinase 2 in myocardial ischaemia-reperfusion injury. Heart. 98:656–662. 2012. View Article : Google Scholar : PubMed/NCBI
28	Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G and Schulz R: Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation. 106:1543–1549. 2002. View Article : Google Scholar : PubMed/NCBI
29	Li Y, Fang J, Hua Y, Wang C, Mu D and Zhou K: The study of fetal rat model of intra-amniotic isoproterenol injection induced heart dysfunction and phenotypic switch of contractile proteins. Biomed Res Int. 2014:3606872014. View Article : Google Scholar : PubMed/NCBI
30	Lin H Bin, Cadete VJJ, Sra B, Sawicka J, Chen Z, Bekar LK, Cayabyab F and Sawicki G: Inhibition of MMP-2 expression with siRNA increases baseline cardiomyocyte contractility and protects against simulated ischemic reperfusion injury. Biomed Res Int. 2014:8103712014. View Article : Google Scholar : PubMed/NCBI
31	Tsutsui H, Kinugawa S and Matsushima S: Oxidative stress and heart failure. Am J Physiol Hear Circ Physiol. 301:H2181–H2190. 2011. View Article : Google Scholar : PubMed/NCBI
32	Wang W, Sawicki G and Schulz R: Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovasc Res. 53:165–174. 2002. View Article : Google Scholar : PubMed/NCBI
33	Krzywonos-Zawadzka A, Franczak A, Olejnik A, Radomski M, Gilmer JF, Sawicki G, Woźniak M and Bil-Lula I: Cardioprotective effect of MMP-2-inhibitor-NO-donor hybrid against ischaemia/reperfusion injury. J Cell Mol Med. 23:2836–2848. 2019. View Article : Google Scholar : PubMed/NCBI
34	Nattel S: Close connections between contraction and rhythm: A new genetic cause of atrial fibrillation/cardiomyopathy and what it can teach us. Eur Heart J. 38:35–37. 2017. View Article : Google Scholar : PubMed/NCBI
35	Hernandez OM, Jones M, Guzman G and Szczesna-Cordary D: Myosin essential light chain in health and disease. Am J Physiol Hear Circ Physiol. 292:H1643–H1654. 2007. View Article : Google Scholar : PubMed/NCBI
36	Kopylova G, Nabiev S, Nikitina L, Shchepkin D and Bershitsky S: The properties of the actin-myosin interaction in the heart muscle depend on the isoforms of myosin but not of α-actin. Biochem Biophys Res Commun. 476:648–653. 2016. View Article : Google Scholar : PubMed/NCBI
37	Sheehy SP, Pasqualini F, Grosberg A, Park SJ, Aratyn-Schaus Y and Parker KK: Quality metrics for stem cell-derived cardiac myocytes. Stem Cell Reports. 2:282–294. 2014. View Article : Google Scholar : PubMed/NCBI
38	Shchepkin DV, Nikitina LV, Bershitsky SY and Kopylova GV: The isoforms of α-actin and myosin affect the Ca²⁺ regulation of the actin-myosin interaction in the heart. Biochem Biophys Res Commun. 490:324–329. 2017. View Article : Google Scholar : PubMed/NCBI
39	Morano I and Haase H: Different actin affinities of human cardiac essential myosin light chain isoforms. FEBS Lett. 408:71–74. 1997. View Article : Google Scholar : PubMed/NCBI
40	Biały D, Wawrzyńska M, Bil-Lula I, Krzywonos-Zawadzka A, Sapa-Wojciechowska A, Arkowski J, Woźniak M and Sawicki G: Low frequency electromagnetic field decreases ischemia-reperfusion injury of human cardiomyocytes and supports their metabolic function. Exp Biol Med (Maywood). 243:809–816. 2018. View Article : Google Scholar : PubMed/NCBI
41	Heussen C and Dowdle EB: Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem. 102:196–202. 1980. View Article : Google Scholar : PubMed/NCBI
42	Barton PJ and Buckingham ME: The myosin alkali light chain proteins and their genes. Biochem J. 231:249–261. 1985. View Article : Google Scholar : PubMed/NCBI
43	Logvinova DS, Matyushenko AM, Nikolaeva OP, Nikolaeva OP and Levitsky DI: Transient interaction between the N-terminal extension of the essential light chain-1 and motor domain of the myosin head during the ATPase cycle. Biochem Biophys Res Commun. 495:163–167. 2018. View Article : Google Scholar : PubMed/NCBI
44	Haase H, Dobbernack G, Tünnemann G, Karczewski P, Cardoso C, Petzhold D, Schlegel WP, Lutter S, Pierschalek P, Behlke J and Morano I: Minigenes encoding N-terminal domains of human cardiac myosin light chain-1 improve heart function of transgenic rats. FASEB J. 20:865–873. 2006. View Article : Google Scholar : PubMed/NCBI
45	Sutsch G, Brunner UT, Von Schulthess C, Hirzel HO, Hess OM, Turina M, Krayenbuehl HP and Schaub MC: Hemodynamic performance and myosin light chain-1 expression of the hypertrophied left ventricle in aortic valve disease before and after valve replacement. Circ Res. 70:1035–1043. 1992. View Article : Google Scholar : PubMed/NCBI
46	Cummins P: Transitions in human atrial and ventricular myosin light-chain isoenzymes in response to cardiac-pressure-overload-induced hypertrophy. Biochem J. 205:195–204. 1982. View Article : Google Scholar : PubMed/NCBI
47	Diffee GM, Seversen EA, Stein TD and Johnson JA: Microarray expression analysis of effects of exercise training: Increase in atrial MLC-1 in rat ventricles. Am J Physiol Hear Circ Physiol. 284:H830–H837. 2003. View Article : Google Scholar : PubMed/NCBI
48	Fujimoto K, Yasue H, Nakao K, Yamamoto H, Hitoshi Y, Jougasaki M, Okumura K, Ogawa H, Takatsu K and Miyamoto E: Novel monoclonal antibodies specific for human cardiac myosin light-chain 1: Useful tools for analysis of normal and pathological hearts. J Histochem Cytochem. 41:35–42. 1993. View Article : Google Scholar : PubMed/NCBI
49	Schaub MC, Tuchschmid CR, Srihari T and Hirzel HO: Myosin isoenzymes in human hypertrophic hearts. Shift in atrial myosin heavy chains and in ventricular myosin light chains. Eur Heart J. 5 (Suppl F):S85–S93. 1984. View Article : Google Scholar : PubMed/NCBI
50	Olejnik A, Krzywonos-Zawadzka A, Banaszkiewicz M and Bil-Lula I: Ameliorating effect of Klotho protein on rat heart during I/R injury. Oxid Med Cell Longev. 2020:64272842020. View Article : Google Scholar : PubMed/NCBI
51	Cadete VJJ, Sawicka J, Jaswal JS, Lopaschuk GD, Schulz R, Szczesna-Cordary D and Sawicki G: Ischemia/reperfusion-induced myosin light chain 1 phosphorylation increases its degradation by matrix metalloproteinase 2. FEBS J. 279:2444–2454. 2012. View Article : Google Scholar : PubMed/NCBI
52	Turer AT and Hill JA: Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy. Am J Cardiol. 106:360–368. 2010. View Article : Google Scholar : PubMed/NCBI
53	Bil-Lula I, Krzywonos-Zawadzka A, Sawicka J, Bialy D, Wawrzynska M, Wozniak M and Sawicki G: L-NAME improves doxycycline and ML-7 cardioprotection from oxidative stress. Front Biosci (Landmark Ed). 23:298–309. 2018. View Article : Google Scholar : PubMed/NCBI
54	Banaszkiewicz M, Krzywonos-Zawadzka A, Olejnik A and Bil-Lula I: Tissue expression of atrial and ventricular myosin light chains in the mechanism of adaptation to oxidative stress. Int J Mol Sci. 21:83842020. View Article : Google Scholar : PubMed/NCBI
55	Cheung PY, Sawicki G, Wozniak M, Wang W, Radomski MW and Schulz R: Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation. 101:1833–1839. 2000. View Article : Google Scholar : PubMed/NCBI
56	Ben-Yosef Y, Lahat N, Shapiro S, Bitterman H and Miller A: Regulation of endothelial matrix metalloproteinase-2 by hypoxia/reoxygenation. Circ Res. 90:784–791. 2002. View Article : Google Scholar : PubMed/NCBI